Orexo licenses Abstral to Invida for in Asia Pacific: GlaxoSmithKline gets rights to bilastine in Spain and Poland

Sweden’s Orexo AB (STO:ORX) has signed an exclusive licensing and distribution agreement with the Singapore-based Invida Group, covering the Asia Pacific region for its Abstral (fentanyl) transmucosal tablets, a treatment for breakthrough cancer pain.

Under the terms of the deal, Orexo will supply Invida with Abstral product, and Invida will be responsible for all regulatory, medical, marketing and sales activities in 11 countries across Asia Pacific, excluding China where the product is already partnered. This accord extends to Australia, India, the Philippines, South Korea, Singapore, Indonesia, Malaysia, Taiwan, Thailand, Vietnam and New Zealand. Financial terms were not disclosed.

Thomas Lundqvist, acting chief executive of Orexo, said: "Invida has a strong market position in the region, and we firmly believe that the company will effectively commercialize Abstral. Partner agreements are an important source for generating additional profitability from Abstral on a global basis”